Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 157, Issue 4, Pages 413-425Publisher
WILEY
DOI: 10.1111/j.1365-2141.2012.09107.x
Keywords
myelofibrosis; stem cell transplant; splenectomy; JAK inhibitors
Categories
Funding
- Medical Research Council [G84/6443] Funding Source: Medline
- MRC [G84/6443] Funding Source: UKRI
- Medical Research Council [G84/6443] Funding Source: researchfish
Ask authors/readers for more resources
Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available